Rephlmmune Biotechnology Inc.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and
Founded Year
2023
Unified Business No.
94106815
Status
Active
Number of Employees
0
Total Paid-in
Capital
18,702,173 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
United States of America
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
RephImmune is a preclinical-stage biotech company incubated in Boston and incorporated in Taiwan. We are dedicated to revolutionizing solid tumor cell therapy through our groundbreaking technology, RACE (Reconstitute-Immunity Antigen-Cell Engager): a unique engine in engineered cell therapy. Unlike conventional cell therapies, RACE bypasses traditional signaling pathways, unlocking the full potential of immune cells. With unparalleled advantages evident in pre-clinical data, RACE stands out in transformative advancements. Join us in accelerating RACE breakthroughs to have a clinical impact on more cancer patients!
